PD-L1 IHC 22C3 pharmDx
Agilent Technologies, Inc. · Decision date Feb 11, 2026
What did the FDA approve?
FDA records P150013/S032 as a supplement to PMA P150013, with the supplement type “Panel Track”. The recorded decision is approval, dated Feb 11, 2026.
FDA approval order statement
Approval for the PD-L1 IHC 22C3 pharmDx for expanding the indications to include use as an aid in identifying patients with esophageal or GEJ carcinoma for treatment with KEYTRUDA (pembrolizumab).
- Regulatory pathway
- PMA supplement
- Supplement type
- Panel Track
- Clinical specialty
- Pathology
- Decision date
- Feb 11, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P150013/S032
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- Decision code
- APPR
- Decision date
- Feb 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.
- Applicant
- Agilent Technologies, Inc.
- Product code
- PLS
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150013 · Original PMA
PD-L1 IHC 22C3 PHARMDX
P150013/S028 · Related supplement
PD-L1 IHC 22C3 pharmDx (Dako Omnis)
P150013/S032 received
Application receipt date recorded by FDA.
P150013/S033 · Related supplement
PD-L1 IHC 22C3 pharmDx
P150013/S032 · FDA decision
Panel Track
P150013/S031 · Related supplement
PD-L1 IHC 22C3 pharmDx
P150013/S035 · Related supplement
PD-L1 IHC 22C3 pharmDx
P150013/S034 · Related supplement
PD-L1 IHC 22C3 pharmDx
Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 22C3 PHARMDXP150013 | Agilent Technologies, Inc. | PMA approval | Oct 2, 2015 | FDA |
PD-L1 IHC 22C3 pharmDx (Dako Omnis)P150013/S028 | Agilent Technologies, Inc. | PMA supplement | Aug 4, 2025 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S033 | Agilent Technologies, Inc. | PMA supplement | Feb 10, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S031 | Agilent Technologies, Inc. | PMA supplement | Mar 19, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S035 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
PD-L1 IHC 22C3 pharmDxP150013/S034 | Agilent Technologies, Inc. | PMA supplement | Sep 21, 2026 | FDA |
Explore the linked device profile
Other records with product code PLS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PD-L1 IHC 28-8 pharmDxP150025/S018 | Agilent Technologies, Inc. | PMA supplement | Jul 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 5301 Stevens Creek Blvd., Santa Clara, CA, 95051
Sources and methodology
- Original FDA record: P150013/S032
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


